Cargando…

Analysis and Identification of Bioactive Compounds of Cannabinoids in Silico for Inhibition of SARS-CoV-2 and SARS-CoV

Despite the approval of multiple vaccinations in different countries, the majority of the world’s population remains unvaccinated due to discrepancies in vaccine distribution and limited production capacity. The SARS-CoV-2 RBD-ACE2 complex (receptor binding domain that binds to ACE2) could be a suit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chenxiao, Liang, Hao, Deng, Yanchun, Yang, Xiushi, Li, Xiaoming, Hou, Chunsheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775500/ https://www.ncbi.nlm.nih.gov/pubmed/36551156 http://dx.doi.org/10.3390/biom12121729

Ejemplares similares

Cannabinoids for SARS-CoV-2 and is there evidence of their therapeutic efficacy?
por: ONAY, Ahmet, et al.
Publicado: (2021)

Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico
por: Sada, Mitsuru, et al.
Publicado: (2020)

In-silico approaches for identification of compounds inhibiting SARS-CoV-2 3CL protease
por: Zeyaullah, Md., et al.
Publicado: (2023)

Comparative analysis of non structural protein 1 of SARS-CoV2 with SARS-CoV1 and MERS-CoV: An in silico study
por: Chaudhuri, Ankur
Publicado: (2021)

Comparative highlights on MERS-CoV, SARS-CoV-1, SARS-CoV-2, and NEO-CoV
por: Goyal, Rajat, et al.
Publicado: (2022)

Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An in silico approach
por: Rangsinth, Panthakarn, et al.
Publicado: (2021)

Structure- and Ligand-Based in silico Studies towards the Repurposing of Marine Bioactive Compounds to Target SARS-CoV-2
por: Fayed, Marwa A.A., et al.
Publicado: (2021)

In-silico evaluation of bioactive compounds from tea as potential SARS-CoV-2 nonstructural protein 16 inhibitors
por: Singh, Rahul, et al.
Publicado: (2021)

Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?
por: Rossi, Francesca, et al.
Publicado: (2020)

Human Coronaviruses SARS-CoV, MERS-CoV, and SARS-CoV-2 in Children
por: Aleebrahim-Dehkordi, Elahe, et al.
Publicado: (2021)

Data mining of coronavirus: SARS-CoV-2, SARS-CoV and MERS-CoV
por: Huh, Jung Eun, et al.
Publicado: (2021)

SARS-CoV, MERS-CoV and SARS-CoV-2: A Diagnostic Challenge
por: Ezhilan, Madeshwari, et al.
Publicado: (2021)

A Review of SARS-CoV2: Compared With SARS-CoV and MERS-CoV
por: Zhou, Huan, et al.
Publicado: (2021)

Transmission Cycle of SARS-CoV and SARS-CoV-2
por: Yadav, Tushar, et al.
Publicado: (2020)

Target-Based In Silico Screening for Phytoactive Compounds Targeting SARS-CoV-2
por: Zhao, Yong, et al.
Publicado: (2021)

In-silico studies of inhibitory compounds against protease enzymes of SARS-CoV-2
por: Khan, Saba, et al.
Publicado: (2023)

In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives
por: Sohail, Muhammad Saqib, et al.
Publicado: (2021)

Evaluation of bioactive compounds from Boswellia serrata against SARS-CoV-2
por: Roy, Arpita, et al.
Publicado: (2021)

SARS-CoV, MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development
por: de Souza Silva, Guilherme Antonio, et al.
Publicado: (2020)

SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
por: Abdelghany, T.M., et al.
Publicado: (2021)

Imaging findings in coronavirus infections: SARS-CoV, MERS-CoV, and SARS-CoV-2
por: Franquet, Tomas, et al.
Publicado: (2020)

Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
por: Aherfi, Sarah, et al.
Publicado: (2021)

Comparative susceptibility of SARS-CoV-2, SARS-CoV, and MERS-CoV across mammals
por: Li, Meng, et al.
Publicado: (2023)

Identification of potent compounds against SARs-CoV-2: An in-silico based drug searching against Mpro
por: Hassam, Muhammad, et al.
Publicado: (2022)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Petersen, Eskild, et al.
Publicado: (2020)

Correction to: Transmission Cycle of SARS-CoV and SARS-CoV-2
por: Yadav, Tushar, et al.
Publicado: (2020)

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics
por: Standl, Fabian, et al.
Publicado: (2021)

Amyloidogenic proteins in the SARS-CoV and SARS-CoV-2 proteomes
por: Bhardwaj, Taniya, et al.
Publicado: (2023)

An in silico map of the SARS-CoV-2 RNA Structurome
por: Andrews, Ryan J., et al.
Publicado: (2020)

In silico antibody engineering for SARS-CoV-2 detection
por: Martí, Didac, et al.
Publicado: (2021)

Identification and quantification of bioactive compounds suppressing SARS-CoV-2 signals in wastewater-based epidemiology surveillance
por: Bayati, Mohamed, et al.
Publicado: (2022)

Palindromic target site identification in SARS-CoV-2, MERS-CoV and SARS-CoV-1 by adopting CRISPR-Cas technique
por: Ghosh, Nimisha, et al.
Publicado: (2022)

In silico exploration of binding potentials of anti SARS-CoV-1 phytochemicals against main protease of SARS-CoV-2
por: Al-Sehemi, Abdullah G., et al.
Publicado: (2022)

Computational analysis of SARS-CoV-2, SARS-CoV, and MERS-CoV genome using MEGA
por: Sohpal, Vipan Kumar
Publicado: (2020)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
por: Zhang, Yun-yu, et al.
Publicado: (2020)

Comparison of the COVID-2019 (SARS-CoV-2) pathogenesis with SARS-CoV and MERS-CoV infections
por: Fani, Mona, et al.
Publicado: (2020)

The emerging SARS-CoV, MERS-CoV, and SARS-CoV-2: An insight into the viruses zoonotic aspects
por: Al-Salihi, Karima A., et al.
Publicado: (2021)

SARS-CoV-2 Inhibition by Sulfonated Compounds
por: Gasbarri, Matteo, et al.
Publicado: (2020)

SARS-CoV2 billion-compound docking
por: Rogers, David M., et al.
Publicado: (2023)

Protease Inhibitory Effect of Natural Polyphenolic Compounds on SARS-CoV-2: An In Silico Study
por: Singh, Rajveer, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kafdv971sp6fp3s8slgj1h69o7